Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Small Molecule Healthcare Contract Manufacturing Market Size, Share & Trends Analysis Report by Type (API, Finished Drug Product), Therapeutic Area and Region with Growth Forecasts, 2025-2033" has been added to ResearchAndMarkets.com's offering.
The global small molecule healthcare contract manufacturing market is experiencing substantial growth, with an estimated size of USD 109.04 billion in 2024, projected to reach USD 310.6 billion by 2033. This marks a robust CAGR of 12.56% from 2025 to 2033.
Key drivers of this growth include the increasing demand for cost-efficient drug production, a burgeoning pipeline of small molecule therapeutics, and a notable shift towards outsourcing among pharmaceutical companies keen on enhancing R&D and commercialization efforts.
The trend of outsourcing stems from pharmaceutical companies' needs to cut down operational costs, boost flexibility, and fast-track time-to-market. Developing and bringing small-molecule drugs to market involves substantial capital and specialized infrastructure, leading companies to depend on contract manufacturing organizations (CMOs) for production efficiency. The surge in demand for both generic and branded small molecule drugs, especially for chronic conditions like cancer, cardiovascular disorders, and diabetes, further emphasizes the need for scalable, high-quality manufacturing services.
Innovation in manufacturing technology, including process chemistry, analytical methods, and continuous manufacturing, is enhancing production efficiency and yield. There is also a growing focus on high-potency active pharmaceutical ingredients (HPAPIs) and complex formulations, prompting partnerships with specialized CDMOs that boast advanced containment and regulatory capabilities.
Market Segmentation Overview
Service Outlook (Revenue, USD Million, 2021-2033)
- API
- Development & Scale-up Services
- Finished dose formulations
- Packaging
Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Cardiovascular Disease
- Neurological Disorders
- Infectious Diseases
- Orthopedic Diseases
- Metabolic Disorders
- Autoimmune Diseases
- Gastrointestinal Disorders
- Respiratory Diseases
- Ophthalmology
- Dental Diseases
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $109.04 Billion |
| Forecasted Market Value (USD) by 2033 | $310.6 Billion |
| Compound Annual Growth Rate | 12.5% |
| Regions Covered | Global |
Companies Featured
- Lonza Group
- Catalent Inc.
- Recipharm AB
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- Cambrex Corporation
- Siegfried Holding AG
- Eurofins Scientific
- PCI Pharma Services
- CordenPharma
For more information about this report visit https://www.researchandmarkets.com/r/6o9i7z
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
